AstraZeneca Medicare Part D patient assistance program no longer requires co-pays

AstraZeneca Medicare Part D patient assistance program no longer requires co-pays
Published date :Dec 8, 2009
Expired date :Dec 8, 2010
December 8, 2009 - Wilmington, DE - AstraZeneca (NYSE:AZN) announced today that patients enrolled in the company's  Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

Prescriptions also now will be mailed to patients' homes or physician's offices under the changes to the AZ&MeTM Prescription Savings program for people with Medicare Part D. The changes will take effect Jan. 1, 2010.

"These changes will better serve Medicare Part D enrollees by making it easier for them to access the medicines they need," said Rich Fante, US President, AstraZeneca Pharmaceuticals LP.  "This prescription savings program and these latest improvements reflect our ongoing commitment to patient health."

Currently, patients enrolled in the program fill their AstraZeneca prescriptions at retail pharmacies and have a co-pay of between $15 and $25, depending on their qualifying income. The elimination of a co-pay will save approximately 30,000 patients enrolled in the program a total of $3 million each year.

Program Details

Eligible patients can enroll in the AZ&MeTM Prescription Savings program for people with Medicare Part D at any time in the calendar year, but must meet program requirements in order to start utilizing the benefit.

The AZ&MeTM Prescription Savings program for people with Medicare Part D is one of three distinct prescription savings programs in the AZ&Me Prescription Savings Program suite. Other AZ&Me Prescription Savings Programs include a plan for individuals without insurance and one for healthcare facilities.

To learn if you qualify for the AZ&Me Prescription Savings Programs, please visit www.AZandMe.com or call 1-800-AZandMe. Program specialists are available Monday through Friday between the hours of 9:00 AM and 5:00 PM EST.

Other prescription savings programs are available regardless of which medications your doctors prescribe. To find out more about the more than 475 savings programs covering 2,500 medications, please visit www.pparx.org or call 1-888-4PPA-NOW (1-888-477-2669).


--------------------------------------------------------------------------------

About AstraZeneca
AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.  In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.  

For more information about AstraZeneca in the US or our AZ&MeTM Prescription Savings programs, please visit: www.astrazeneca-us.com.  

Media Contacts: 

Tiffany Burke , AstraZeneca: 302-885-4995
.Page tools
Print
Bookmark this page
Subscribe to RSS news feed
Stay connected with us


Stay connected with us on our social media sites

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.